Cargando…

Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study

We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Guh, Daphne P., Mohammadi, Tima, Pataky, Reka E., Tam, Alexander C. T., Lynd, Larry D., Conklin, Annalijn I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047657/
https://www.ncbi.nlm.nih.gov/pubmed/36975453
http://dx.doi.org/10.3390/curroncol30030240
_version_ 1785013980068052992
author Zhang, Wei
Guh, Daphne P.
Mohammadi, Tima
Pataky, Reka E.
Tam, Alexander C. T.
Lynd, Larry D.
Conklin, Annalijn I.
author_facet Zhang, Wei
Guh, Daphne P.
Mohammadi, Tima
Pataky, Reka E.
Tam, Alexander C. T.
Lynd, Larry D.
Conklin, Annalijn I.
author_sort Zhang, Wei
collection PubMed
description We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years at diagnosis with PCa between 2010 and 2017 (Cohort 1) from the diagnosis date until the date of death, the last date of observation, or 31 December 2019. Patients who died from PCa after 1 January 2010, were selected for Cohort 2. PCa attributable costs were estimated by comparing costs in patients to matched controls. Cohort 1 (n = 22,672) had a mean age of 69.9 years (SD = 8.9) and a median follow-up time of 5.2 years. Cohort 2 included 6942 patients. Mean PCa attributable costs were the highest during the first year after diagnosis ($14,307.9 [95% CI: $13,970.0, $14,645.8]) and the year before death ($9959.7 [$8738.8, $11,181.0]). Primary treatment with radiation therapy had significantly higher costs each year after diagnosis than a radical prostatectomy or other surgeries in advanced-stage PCa. Androgen deprivation therapy (and/or chemotherapy) had the highest cost for high-grade and early-stage cancer during the three years after diagnosis. No treatment group had the lowest cost. Updated cost estimates could inform economic evaluations and decision-making.
format Online
Article
Text
id pubmed-10047657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100476572023-03-29 Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study Zhang, Wei Guh, Daphne P. Mohammadi, Tima Pataky, Reka E. Tam, Alexander C. T. Lynd, Larry D. Conklin, Annalijn I. Curr Oncol Article We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years at diagnosis with PCa between 2010 and 2017 (Cohort 1) from the diagnosis date until the date of death, the last date of observation, or 31 December 2019. Patients who died from PCa after 1 January 2010, were selected for Cohort 2. PCa attributable costs were estimated by comparing costs in patients to matched controls. Cohort 1 (n = 22,672) had a mean age of 69.9 years (SD = 8.9) and a median follow-up time of 5.2 years. Cohort 2 included 6942 patients. Mean PCa attributable costs were the highest during the first year after diagnosis ($14,307.9 [95% CI: $13,970.0, $14,645.8]) and the year before death ($9959.7 [$8738.8, $11,181.0]). Primary treatment with radiation therapy had significantly higher costs each year after diagnosis than a radical prostatectomy or other surgeries in advanced-stage PCa. Androgen deprivation therapy (and/or chemotherapy) had the highest cost for high-grade and early-stage cancer during the three years after diagnosis. No treatment group had the lowest cost. Updated cost estimates could inform economic evaluations and decision-making. MDPI 2023-03-08 /pmc/articles/PMC10047657/ /pubmed/36975453 http://dx.doi.org/10.3390/curroncol30030240 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Wei
Guh, Daphne P.
Mohammadi, Tima
Pataky, Reka E.
Tam, Alexander C. T.
Lynd, Larry D.
Conklin, Annalijn I.
Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title_full Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title_fullStr Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title_full_unstemmed Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title_short Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study
title_sort health care costs attributable to prostate cancer in british columbia, canada: a population-based cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047657/
https://www.ncbi.nlm.nih.gov/pubmed/36975453
http://dx.doi.org/10.3390/curroncol30030240
work_keys_str_mv AT zhangwei healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT guhdaphnep healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT mohammaditima healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT patakyrekae healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT tamalexanderct healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT lyndlarryd healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy
AT conklinannalijni healthcarecostsattributabletoprostatecancerinbritishcolumbiacanadaapopulationbasedcohortstudy